Yesterday, Oct. 22, 2015, 32 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,441.25 to $4,000,000.00.

Highlighted Stocks Traded by Insiders:

Steris (STE) - FREE Research Report

Carestio Daniel A, who is Sr. V. P., Isomedix & Life Sci at Steris, sold 881 shares at $68.25 on Oct. 22, 2015. Following this transaction, the Sr. V. P., Isomedix & Life Sci owned 23,070 shares meaning that the stake was reduced by 3.68% with the 881-share transaction.

The shares most recently traded at $67.89, down $0.36, or 0.53% since the insider transaction. Historical insider transactions for Steris go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 21,826

The average volume for Steris has been 734,300 shares per day over the past 30 days. Steris has a market cap of $4.1 billion and is part of the health care sector and health services industry. Shares are up 4.29% year-to-date as of the close of trading on Thursday.

STERIS Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The stock currently has a dividend yield of 1.45%. The company has a P/E ratio of 31.1. Currently, there are 2 analysts who rate Steris a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STE - FREE

TheStreet Quant Ratings rates Steris as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Steris Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 3,177 shares at $24.25 on Oct. 22, 2015. Following this transaction, the Shareholder owned 806,220 shares meaning that the stake was reduced by 0.39% with the 3,177-share transaction.

The shares most recently traded at $25.25, up $1.00, or 3.96% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 28,198
  • 12-Week # shares sold: 91,926
  • 24-Week # shares sold: 187,987

The average volume for Village Super Market has been 25,000 shares per day over the past 30 days. Village Super Market has a market cap of $237.4 million and is part of the services sector and retail industry. Shares are down 8.59% year-to-date as of the close of trading on Thursday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 4.15%. The company has a P/E ratio of 11.2. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PacWest Bancorp (PACW) - FREE Research Report

Rusnak Patrick J, who is EVP, Chief Financial Officer at PacWest Bancorp, bought 2,400 shares at $43.09 on Oct. 22, 2015. Following this transaction, the EVP, Chief Financial Officer owned 49,250 shares meaning that the stake was boosted by 5.12% with the 2,400-share transaction.

The shares most recently traded at $44.50, up $1.41, or 3.17% since the insider transaction. Historical insider transactions for PacWest Bancorp go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 15,000
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 281,000

The average volume for PacWest Bancorp has been 722,100 shares per day over the past 30 days. PacWest Bancorp has a market cap of $4.4 billion and is part of the financial sector and banking industry. Shares are down 3.32% year-to-date as of the close of trading on Thursday.

PacWest Bancorp operates as the holding company for Pacific Western Bank that provides commercial banking products and services to individuals, professionals, and small to mid-sized businesses in the United States. It accepts demand, money market, and time deposits. The stock currently has a dividend yield of 4.65%. The company has a P/E ratio of 14.5. Currently, there are 6 analysts who rate PacWest Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PACW - FREE

TheStreet Quant Ratings rates PacWest Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full PacWest Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.